# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amge...
Baltimore secures an $80 million settlement with Teva Pharmaceuticals in its opioid crisis litigation. Funds will be allocated ...
- Reuters
- Reuters
AbbVie (NYSE:ABBV), today announced that Health Canada has approved CONSTELLA® (linaclotide) as a once-daily oral treatment for...
Full data from the primary analysis of the positive, single-arm Phase 2 PICCOLO trial, evaluating mirvetuximab soravtansine (EL...